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Background: The inhaled corticosteroid (ICS) ciclesonide (Cic), controls asthma symptoms 
in the majority of patients at the recommended dose of 160 µg/day. However, the relationship 
between the level of asthma control and increasing doses of Cic is unknown. This study inves-
tigated whether long-term treatment with higher doses of Cic would further improve asthma 
symptoms in patients with uncontrolled asthma despite ICS use.
Patients and methods: In a double-blind, randomized, parallel-group study, 367 patients 
were allocated to one of three treatment arms (Cic 160, 320 and 640 µg/day). After a single-
blind, 3-week baseline period with Cic 160 µg/day, eligible patients were randomized to receive 
52 weeks of treatment with Cic 160, 320 or 640 µg/day (double-blind period) during which 
forced expiratory volume in 1 second (FEV
1
), exacerbations and Asthma Control Questionnaire 
(ACQ) scores were measured.
Results: Treatment with all the three doses was associated with significant improvements in 
ACQ scores, FEV
1
 and asthma symptoms (P<0.01). There were no statistically significant 
differences between the three doses. The results of the primary end point analysis showed a 
numerical improvement in the ACQ score with Cic 640 µg/day compared with Cic 160 µg/day 
(least square [LS] mean: -0.122; two-sided P-value: 0.30). Post hoc subgroup analyses showed 
that the improvement in the ACQ score with Cic 640 µg/day compared with Cic 160 µg/day 
was statistically significant in subjects who experience at least one exacerbation per year (LS 
mean: -0.586; 95% confidence interval: -1.110, -0.062, P=0.0285). Adverse events were low 
and consistent with the known safety profile of Cic.
Conclusion: In patients with persistent, uncontrolled asthma, increasing the Cic dose from 
160 to 640 µg/day provided no clear additional effect. Patients who experience more than one 
exacerbation per year may benefit from higher doses; however, further studies are necessary to 
confirm this. All Cic doses were well tolerated.
Keywords: dose-response, asthma control
Introduction
The primary aim of asthma management is to achieve good overall asthma control, 
which consists of two domains.1–3 The first is current asthma control, which includes 
the day-to-day minimization of both daytime and nighttime symptoms, no activity 
limitation, minimal rescue bronchodilator use and no airway narrowing. The second 
domain includes minimizing the future risk of severe asthma exacerbations.
The Asthma Control Questionnaire (ACQ) is a validated composite score based 
on symptoms, activities, use of rescue medication and measurement of airway cali-
ber over 1 week.2 The score reflects the adequacy of asthma control and changes in 
Correspondence: Søren E Pedersen 
Pediatric Research Unit, Kolding Hospital, 
University of Southern Denmark, 
Universitetsparken 1, 6000 Kolding, 
Denmark 
Email sp@spconforsk.dk
Journal name: Journal of Asthma and Allergy
Article Designation: ORIGINAL RESEARCH
Year: 2017
Volume: 10
Running head verso: Pedersen et al
Running head recto: CONTRAST study of Cic in asthma
DOI: http://dx.doi.org/10.2147/JAA.S111712
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
11
-A
pr
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36
Pedersen et al
asthma  control that may occur spontaneously or as the result 
of treatment. Asthma is normally considered well controlled 
in patients with an ACQ score of <0.75. Patients with a score 
of ≥1.5 are considered to have poorly-controlled asthma.3 
The accepted minimal important difference in the ACQ 
score is 0.5.4
Numerous studies have confirmed that treatment with 
inhaled corticosteroids (ICS) is associated with an increase 
in the level of asthma control. However, dose–response rela-
tionships between the level of asthma control and increasing 
doses of ICS have been less well studied. The Gaining Opti-
mal Asthma ControL (GOAL) study5 compared the effect 
of increasing doses of fluticasone propionate (FP) and FP 
plus salmeterol on asthma control, as defined by the Global 
Initiative for Asthma (GINA) guidelines, in 3421 patients 
over 1 year. In patients pretreated with ≤500 µg beclometha-
sone dipropionate daily (or an equivalent ICS dose), the 
percentage that achieved well-controlled asthma increased 
by ~20% when the daily dose of fluticasone was increased 
from 200 to 500 µg/day, and by approximately another 10% 
following a further dose increase to 1000 µg/day. Post hoc 
analysis of asthma control in the Formoterol and Corticoste-
roids Establishing Therapy (FACET) study,6 which included 
~200 patients in each study arm, showed that the time with 
 poorly-controlled (GINA-defined) asthma decreased from 
21% to 15% of weeks when the dose of budesonide was 
increased from 200 to 800 µg/day.
The current recommended dose of ciclesonide (Cic) 
is 160 µg once daily.7 This dose leads to asthma control in 
the majority of patients. In patients with severe asthma, a 
12-week study found that a dose of 640 µg/day reduced the 
frequency of exacerbations without an improvement in lung 
function,8 suggesting that the dose–response relationship may 
differ between different outcomes.
The current study (in patients with insufficient asthma 
control during treatment with Cic 160 µg/day) was designed to 
investigate whether long-term treatment with Cic 320 µg/day and 
Cic 640 µg/day for 1 year improves asthma control, measured 
by the ACQ score, lung function and exacerbations.
Patients and methods
Patients
Patients aged 12–70 years with a history of persistent 
asthma and on treatment for at least 6 months with an ICS 
at a stable dose (FP 200–1000 µg/day or equivalent) who 
were insufficiently controlled for a minimum of 12 weeks 
were enrolled. A list of prohibited medications is given in 
the Supplementary materials under the “Exclusion criteria” 
section. The ACQ criteria for inclusion in the baseline period 
are given in Table 1.
Study design
This was a multicenter, double-blind, randomized, parallel-
group study, conducted at 39 centers in five countries: 
Argentina, Brazil, Germany, Israel and Russia. Patients were 
allocated to one of the three treatment arms (Cic 160, 320 
and 640 µg/day) in a 1:1:1 randomization scheme, based 
on a blocked randomization scheme. Eligible patients were 
randomly assigned to treatment by means of a computerized 
Interactive Voice and Web Response System. During the treat-
ment period and until the safety follow-up visit (30 days after 
the end of the study), patients, investigators, site personnel 
and any other parties involved in the study were blinded.
The study composed of a single-blind baseline period 
(3 weeks) during which all patients were treated once a week 
with Cic 160 µg/day to prevent the likelihood of a carryover 
effect from ICS pretreatment such as non-extra-fine particle 
budesonide or fluticasone. This was followed by a double-
blind treatment period (52 weeks) during which all patients 
were treated twice daily with total daily doses of Cic 160, 
320 or 640 µg/day. The visits took place at 6-week intervals, 
except for the first visit, which took place 4 weeks after 
patients were randomized into the study.
The study was approved by the Independent Ethics Com-
mittee for Clinical Pharmacology Trials, the Research Com-
mittee on Ethics and Pharmacology, the INAER Research 
Committee on Ethics (Argentina), the National Health 
Surveillance Agency and National Commission of Ethics in 
Research, the Ethics Committee on Research in Hosts of the 
Hospital Group Conception, the Research Ethics Commit-
tee of the Pontifical Catholic University of Rio Grande do 
Sul, the Research Ethics Committee of the Vila Heliopolis 
Hospital Complex, the Ethics Committee on Research of 
the ABC Medical School, the Research Ethics Committee 
of the Institute of Infectology Emilio Ribas, the Ethics Com-
mittee on Research in Human Beings of the Hospital Padre 
Bento de Guarulhos/SP, the Research Ethics Committee of 
Table 1 ICS pretreatment dose and ACQ at the start of baseline
ICS pretreatment dose ACQ score at the 
start of baseline
Low-dose ICS (FP 200–250 μg/day or 
equivalent)
≥2
Medium- or high-dose ICS  
(FP 251–1000 μg/day or equivalent)
≥0.75 to <2
Abbreviations: ACQ, Asthma Control Questionnaire; FP, fluticasone propionate; 
ICS, inhaled corticosteroid.
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the Center for Medical and PUC, the Federal University of 
Santa Catarina Ethics Committee on Research in Human 
Beings, the Ethics Committee on Research in Human Beings 
Pro-Cardiac-RJ (Brazil), the Ethics Committee of the State 
Chamber of Brandenburg, the Ethics Committee of the 
Bavarian State Chamber of Physicians, the Ethics Committee 
of the State of Berlin, the Ethics Committee of the Medical 
Chamber North Rhine, the Ethics Committee of Landesärz-
tekammer Baden-Württemberg, the Federal Institute for 
Drugs and Medical products (Germany), the Institutional 
Helsinki Committee (Israel) and the Ethics Committees of the 
GBUZ NOS, the St. Petersburg State Medical University, the 
Siberian State Medical University, the City Clinical Hospital 
#2, the City Clinical Hospital n.a., the City Hospital #5, the 
Moscow Research Pulmonology Institute, the Novosibirsk 
State Medical Academy of Roszdrav Krasniy Prospect and 
the Medical Ethics Expert Committee at RMAPO (Russia) 
and was performed according to the Declaration of Helsinki 
and Good Clinical Practice Guidelines. All patients provided 
written informed consent. The clinical trial registration num-
ber is NCT01455194.
Study end points
The primary efficacy end point was the change from the end 
of the baseline period to the last value in the ACQ score. 
Throughout the study, patients completed the ACQ at weekly 
intervals either at investigational sites or at home. Secondary 
efficacy end points included time course of ACQ, analysis 
of asthma control (time to well-controlled asthma and well-
controlled asthma over the course and at the end of the study; 
time to first ACQ improvement and ACQ improvement at the 
end of the study; frequency of patients below ACQ cutoff 
points [0.5, 0.75, 1.0, 1.25 and 1.5] and exploratory subgroup 
analysis to assess the impact of key demographic variables on 
the primary end point), asthma exacerbations and identifica-
tion of patient subsets with markedly high benefits (ie, patient 
subsets that benefited from dose escalation).
Spirometry was performed using portable devices 
( SpiroPro), and it was mandatory that the same device was 
used for all measurements during the study (ie, at the site 
and at home). Forced expiratory volume in 1 second (FEV
1
) 
was recorded at weekly intervals at the site or at the patient’s 
home. All lung function measurements were performed prior 
to inhalation of the study medication. Rescue medication was 
withheld for at least 4 hours prior to each FEV
1
 measurement. 
All recordings were conducted between 06:00 and 10:00 in 
the morning and ±90 min of the first randomization visit time 
for each individual patient.
Patients recorded their asthma symptoms, compliance 
with study treatment and rescue medications in a diary. 
Asthma exacerbations were defined as a worsening of asthma 
requiring treatment with oral or other systemic glucocortico-
steroids for at least 3 days, or a visit to the emergency room 
or hospitalization due to asthma. Inspection of the patient’s 
mouth and throat was performed if the patient reported an 
oropharyngeal adverse event (AE).
Safety
Safety monitoring included AEs, laboratory tests, urinalysis 
and vital signs.
Statistical analysis
For the primary efficacy end point, an analysis of covariance 
of the change in ACQ from baseline to last visit (including 
baseline ACQ and age as covariates, treatment, sex and ICS 
pretreatment dose as factors) was used.
For confirmatory statistical testing, two statistical tests 
were carried out in a hierarchical manner to address mul-
tiplicity. All other efficacy variables were evaluated using 
descriptive statistics. In addition, analyses of covariances or 
comparable nonparametric strategies were applied for con-
tinuous variables. A log-rank test and proportional hazards 
for the analysis of time-to-event variables and a Fisher’s 
exact test were used for dichotomous variables (“Statistical 
methods” section in the Supplementary materials).
Results
Of the 538 screened patients, 520 entered the baseline period 
and 367 were randomized. A total of 89 (24.3%) patients pre-
maturely discontinued and 278 (75.7%) patients completed 
the study (Figure 1).
Demographics
Demographic and baseline characteristics are summarized 
in Tables 2 and S1.
Overall, patient demographics were similar between 
the three treatment groups. The mean age of patients was 
~44 years, and ~63% were female. The majority of the 
patients were white (93.2%) and had never smoked (87.2%). 
The proportion of former smokers differed between treat-
ment groups, with 8.3, 15.6 and 12.0% in the 160, 320 
and 640 µg/day groups, respectively. The mean ACQ score 
at baseline was 2.2, reflecting poorly-controlled asthma. 
Mean baseline FEV
1
 reversibility (percentage of pre-
bronchodilator FEV
1
) was 25.0%. The majority of patients 
had low-to-medium pre-study ICS doses (32.4% were 
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on 201–250 µg/day and 59.1% were on 251–500 µg/day 
beclomethasone-equivalent ICS dose).
Concomitant medication
In general, the types of relevant asthma medications and the 
proportion of patients taking each relevant asthma medica-
tion were similar across the treatment groups. ICS was the 
most commonly used pre-study medication in all treatment 
groups. In line with the study inclusion criteria, where only 
inhaled salbutamol was allowed, the most commonly used 
medication during the baseline and randomized, double-blind 
treatment periods in all the treatment groups was short-acting 
beta 2-agonists (“Concomitant medication” section in the 
Supplementary materials and Table S2).
Primary end point ACQ
Mean ACQ scores improved significantly over the 52-week 
study period with all Cic doses (P<0.0001 in all treat-
ment groups; Table 3). However, there were no significant 
between-group differences in the change in ACQ scores with 
Cic 640 µg/day vs Cic 160 µg/day (least square [LS] mean: 
-0.122; 95% confidence interval [CI]: -0.353, 0.109; two-
sided P-value=0.30).
Subgroup analyses
Subgroup analyses to assess the impact of key baseline demo-
graphic variables (ACQ score, pre-study ICS dose, body mass 
index, smoking status, completers/withdrawals and FEV
1
) on 
the primary end point are given in the “Subgroup analyses” 
section of Supplementary materials and Table S3, and support 
the results of the intention-to-treat analysis.
Post hoc analyses were undertaken to examine the relation-
ship between exacerbation history (categorized as: 0, ≥1 and 
unknown for the year prior to the study period) and change 
in the ACQ score. In the subgroups of no history of exacerba-
tions and unknown history of exacerbations, changes in ACQ 
scores were similar across treatment groups. However, for 
subjects with a history of at least one exacerbation in the year 
prior to the study period, there was a significant difference 
between the mean change in ACQ scores in the Cic 640 µg/day 
Figure 1 Summary of all patients who were enrolled, randomized, completed and discontinued during the study.
Abbreviation: AE, adverse event.
N=538
Screened
n=18
Not treated
Non-randomized
n=520
Entered baseline
n=367
Randomized
n=153 ciclesonide 160 mg/day
Treated non-randomized
Reason for non-randomization:
- Screen failure=20
- Randomization failure=90
- Asthma deterioration=12
- AE=1
- Patient withdrawal=21
- Lost to follow-up=2
- Predefined discontinuation
  criterion fulfilled=3
- Other=4
n=31 discontinued
- Asthma deterioration=6
- AE=1
- Patient withdrawal=16
- Predefined discontinuation
  criterion fulfilled=2
- Other=5
n=30 discontinued
- Asthma deterioration=14
- AE=1
- Patient withdrawal=12
- Lost to follow-up=1
- Pregnancy=1
- Other=1
n=28 discontinued
- Asthma deterioration=9
- AE=3
- Patient withdrawal=9
- Lost to follow-up=1
- Predefined discontinuation
  criterion fulfilled=2
- Other=4
n=120
Ciclesonide 160 µg/day
n=89
Completed
n=92
Completed
n=97
Completed
n=122
Ciclesonide 320 µg/day
n=125
Ciclesonide 640 µg/day
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Table 2 Baseline demographics in the ITT population
Variable Cic dose Total
160 μg/day (N=120) 320 μg/day (N=122) 640 μg/day (N=125) N=367
Age, years
 Mean (SD) 43.2 (14.9) 44.7 (15.6) 45.3 (16.2) 44.4 (15.6)
Sex, male
 n (%) 48 (40.0) 45 (36.9) 44 (35.2) 137 (37.3)
BMI, kg/m2 
 Mean (SD) 27.3 (5.2) 28.4 (6.4) 27.1 (5.4) 27.6 (5.7)
History of exacerbations, n (%)
 0 70 (58.3) 70 (57.4) 63 (50.4) 203 (55.3)
 1 17 (14.2) 19 (15.6) 21 (16.8) 57 (15.5)
 2–3 4 (3.3) 3 (2.5) 4 (3.2) 11 (3.0)
 ≥4 0 0 0 0
 Unknown 29 (24.2) 30 (24.6) 37 (29.6) 96 (26.2)
Smoking status, n (%)*
 Never 109 (90.8) 102 (83.6) 109 (87.2) 320 (87.2)
 Current 1 (0.8) 1 (0.8) 1 (0.8) 3 (0.8)
 Former 10 (8.3) 19 (15.6) 15 (12.0) 44 (12.0)
Pre-study ICS dose, μg/day FP equivalent, n (%)
<200 3 (2.5) 3 (2.5) 2 (1.6) 8 (2.2)
Low: ≥200–≤250 40 (33.3) 37 (30.3) 42 (33.6) 119 (32.4)
Medium: >250–≤500 72 (60.0) 75 (61.5) 70 (56.0) 217 (59.1)
High: >500–≤1000 5 (4.2) 7 (5.7) 11 (8.8) 23 (6.3)
ACQ score
 Mean (SD) 2.24 (0.34) 2.16 (0.38) 2.20 (0.36) 2.20 (0.36)
Pre-bronchodilator FEV1, % (predicted)
 Mean (SD) 69.1 (18.47) 74.4 (16.73) 71.8 (18.44) 71.8 (17.97)
Post-bronchodilator FEV1, % (predicted)
 Mean (SD) 84.9 (19.30) 90.2 (17.74) 88.5 (17.71) 87.9 (18.34)
FEV1 reversibility, % mean (SD) 25.5 (17.02) 23.0 (17.10) 26.5 (20.78) 25.0 (18.41)
Note: *Percentages have been rounded to one decimal place and may not add up to 100%.
Abbreviations: ACQ, Asthma Control Questionnaire; BMI, body mass index; Cic, ciclesonide; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate; ICS, 
inhaled corticosteroid; ITT, intention-to-treat; SD, standard deviation.
Table 3 Change from baseline to last visit in ACQ score of within-treatment and between-treatment differences with three Cic doses
Cic dose Mean ACQ score at  
baseline (SE)
LS mean change from baseline  
(SE) (95% CI)
Two-sided  
P-value
Within-treatment differences
 160 μg/day (N=120) 2.24 (0.031) -0.833 (0.1028) (-1.035, -0.630) <0.0001
 320 μg/day (N=119) 2.15 (0.035) -0.799 (0.1019) (-0.999, -0.598) <0.0001
 640 μg/day (N=125) 2.19 (0.032) -0.955 (0.0969) (-1.145, -0.764) <0.0001
Between-treatment differences
 640 vs 160 μg/day
-0.122 (0.1175) (-0.353, 0.109) 0.30
 640 vs 320 μg/day
-0.156 (0.1172) (-0.387, 0.074) 0.18
 320 vs 160 μg/day 0.034 (0.1180) (-0.198, 0.266) 0.77
Note: Data are expressed as mean or LS mean (SE) in the ITT population; LS mean values are from ANCOVA.
Abbreviations: ACQ, Asthma Control Questionnaire; ANCOVA,  analysis of covariance; CI, confidence interval; Cic, ciclesonide; ITT, intention-to-treat; LS, least squares; 
SE, standard error.
treatment group and the Cic 160 µg/day treatment group (LS 
mean: -0.586; 95% CI: -1.110, -0.062, P=0.0285; Table 4).
Analysis of well-controlled asthma 
parameters
The time to well-controlled asthma was similar in all treat-
ment groups (Figure 2).
The number of patients with well-controlled asthma at the 
end of the study was similar across the three patient groups: 31.7, 
36.9 and 40.8% of patients in the Cic 160, 320 and 640 µg/day 
treatment groups, respectively. The difference in the proportion 
of responders was not statistically significant by Fisher’s exact 
test (P=0.15 for comparison of the 160 and 640 µg/day groups, 
and P=0.60 for comparison of the 160 and 320 µg/day groups).
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The difference in the number of weeks with well- 
controlled asthma over the 52-week study period was similar 
in all treatment groups (Table 5).
FEV1
Overall, FEV
1
 results were similar across the double-blind 
treatment groups from baseline to last visit, and there were 
no significant differences (Table 6).
Asthma exacerbations
The hazard ratio for the time to first asthma exacerbation was 
numerically in favor of Cic 640 and 320 µg/day vs Cic 160 
µg/day, but the difference was not statistically significant. A 
total of 26 patients experienced exacerbations during this 
study: n=5, 11 and 10 in the Cic 160, 320 and 640 µg/day 
treatment groups, respectively. The majority of patients were 
treated with oral glucocorticosteroids, and two patients were 
hospitalized.
Safety findings
In total, 57.9% of patients treated with Cic experienced at 
least one AE, with no notable differences in AE frequency 
between treatment groups (Table S4). AEs occurring in at 
least 5% of patients in any treatment group are listed in the 
Supplementary materials.
Discussion
This study is, to our knowledge, the first to assess strict 
dose–response effects of the ICS Cic on asthma control, 
which is a patient-relevant outcome. The results showed that 
160, 320 and 640 µg Cic were all associated with statistically 
significant improvements in ACQ. The differences between 
the three doses were marginal and not statistically significant. 
There were no statistically significant differences across 
the three Cic groups for any of the primary or secondary 
efficacy end points measured. However, post hoc subgroup 
analyses showed that in patients who experience more than 
one exacerbation per year, there was a statistically significant 
improvement in the ACQ score between the Cic 640 µg/day 
treatment group and the Cic 160 µg/day treatment group, sug-
gesting that increasing the dose of ICS may improve asthma 
control in patients with frequent exacerbations.
Our findings mirror previous studies that investigated 
dose–response relationships of Cic.8,9 Bateman et al8 treated 
680 patients with Cic 160 or 640 µg/day over a 12-week 
period. The results demonstrated that statistically significant 
effects between the treatment groups were observed for some 
of the efficacy end points such as time to first exacerbation, 
morning peak expiratory flow and asthma symptom score. 
However, as in the current study, no statistically significant 
differences in FEV
1
 increases were seen between the groups 
treated with the two doses, while asthma control was not 
Figure 2 Kaplan–Meier plot of time from randomization to well-controlled asthma 
in the ITT population.
Abbreviations: Cic, ciclesonide; ITT, intention-to-treat.
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Table 4 LS mean change from baseline to last visit in ACQ score of between-treatment differences with Cic 640, 320 
and 160 μg/day by exacerbation history subgroups (ITT)
Variable Cic 160 μg/day 
(N=120); n (%)
Cic 320 μg/day 
(N=122); n (%)
Cic 640 μg/day 
(N=125); n (%)
Change in ACQ score  
Cic 640 μg/day vs Cic 160 μg/day;  
Cic 320 μg/day vs Cic 160 μg/day
LS mean (SE) 95% CI Two-sided P-value
Exacerbation history*
≥1 21 (17.5) 22 (18.0) 25 (20.0) -0.586 (0.2663); 
0.468 (0.2751)
-1.110, -0.062; 
-0.073, 1.009
0.0285; 0.0898
0 70 (58.3) 70 (57.4) 63 (50.4) 0.019 (0.1540); 
-0.108 (0.1505)
-0.284, 0.322;  
-0.404, 0.188
0.9035; 0.4734
Unknown 29 (24.2) 30 (24.6) 37 (29.6)
-0.101 (0.2216); 
0.034 (0.2332)
-0.537, 0.335; 
-0.425, 0.492
0.6494; 0.8855
Notes: *Post hoc subgroup analysis. Exacerbation history subgroups categorized according to the number of exacerbations in the previous year. LS mean values are from 
ANCOVA.
Abbreviations: ACQ, Asthma Control Questionnaire; ANCOVA, analysis of covariance; Cic, ciclesonide; CI, confidence interval; ITT, intention-to-treat; LS, least squares; 
SE, standard error.
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Table 5 Analysis of well-controlled asthma parameters over 52 weeks of treatment
Variable Cic 160 μg/day Cic 320 μg/day Cic 640 μg/day Change in ACQ score  
Cic 640 μg/day vs Cic 160 μg/day;  
Cic 320 μg/day vs Cic 160 μg/day;  
Cic 640 μg/day vs Cic 320 μg/day 
Hodges–Lehmann point 
estimate/HR*
95% CI P-value
Number of weeks of well-controlled asthma, Wilcoxon–Mann–Whitney score**
Total 1211/5286 (22.9) 1514/5388 (28.1) 1447/5669 (25.5) 0.0
-3.0, 4.0 0.85
1.0
-2.0, 5.0 0.42
-1.0 -4.0, 3.0 0.69
ACQ cutoff point
0.5 719/5286 (13.6) 936/5388 (17.4) 944/5669 (16.7) 1.0
-1.0, 4.0 0.31
0.0
-2.0, 4.0 0.71
1.0
-2.0, 4.0 0.60
1 1726/5286 (32.7) 2182/5388 (40.5) 2026/5669 (35.7) 2.0
-1.0, 7.0 0.22
4.0 0.0, 8.0 0.06
-1.0 -5.0, 3.0 0.57
1.25 2003/5286 (37.9) 2468/5388 (45.8) 2327/5669 (41.0) 2.0
-1.0, 7.0 0.24
4.0
-1.0, 9.0 0.10
-1.0 -6.0, 3.0 0.64
1.5 2512/5286 (47.5) 2934/5388 (54.5) 2858/5669 (50.4) 2.0
-2.0, 6.0 0.33
3.0
-1.0, 7.0 0.18
-1.0 -5.0, 3.0 0.65
Number of patients with well-controlled asthma at study end, Fisher’s exact text#
Total 38 (31.7) 45 (36.9) 51 (40.8) – – 0.15
0.42
0.60
Time to first well-controlled asthma measurement, log-rank test#
Total 73 (60.8) 84 (68.9) 81 (64.8) 1.0 0.9, 1.2 0.61
1.2 0.9, 1.6 0.25
0.9 0.7, 1.2 0.49
Notes: *Hodges–Lehmann point estimate for Wilcoxon–Mann–Whitney, HR for log-rank test. **Data are n/n′ (%), where n represents the number of weeks with well-
controlled asthma under study treatment across all patients, n′ represents the total number of weeks under study treatment across all patients. #Data are n (%) and represent 
the number of patients who were responders, defined as a patient with ACQ improvement of at least 0.5 at the end of the study, and the percentage of the population 
exposed who were responders.
Abbreviations: ACQ, Asthma Control Questionnaire; CI, confidence interval; Cic, ciclesonide; HR, hazard ratio.
Table 6 Post hoc sensitivity analyses for change from baseline to last visit in FEV1 of between-treatment differences in the ITT population
Cic dose LS mean  
FEV1 (mL) (SE)
Comparison with Cic 160 μg
LS mean difference  
FEV1 (SE)
95% CI Two-sided 
P-value
160 μg/day (N=115) 3 (45) – – –
320 μg/day (N=113) 19 (43) 16 (54) -91, 123 0.77
640 μg/day (N=113) 95 (42) 92 (55) -15, 199 0.09
Note: Data are of between-treatment differences mean or LS mean (SE).
Abbreviations: CI, confidence interval; Cic, ciclesonide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; LS, least squares; SE, standard error.
studied.8 The 367 patients included in the current study had 
few exacerbations and it was not possible to observe differ-
ences between Cic doses on exacerbation frequency.
Previous research using ICS such as FP, budesonide and 
similar drugs at different doses has indicated that dose–
response relationships are rather flat and may be affected 
by multiple factors including study design and the outcome 
parameter measured.7,10 Since an asthma control score is a 
composite of several individual outcomes, we anticipated 
that it might be possible to show dose–response relation-
ships with this outcome, a hypothesis that had never been 
thoroughly studied. Interestingly, Cic was found to be effec-
tive on asthma control at the lowest dose tested (160 µg/day), 
but no dose–response was seen. Treating asthma patients, 
even those with insufficient control with the recommended 
160 µg/day of Cic instead of prescribing a higher dose would 
reduce treatment costs. This approach to asthma treatment is 
in agreement with current GINA guidelines, which favor the 
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use of the lowest dose possible to maintain asthma control. 
Once asthma control has been achieved and maintained, 
GINA recommends avoiding overtreatment by following their 
stepwise approach and reducing the ICS dose.1 The current 
findings support this.
As previously mentioned, post hoc analysis of asthma 
control in the FACET study6 revealed that the time with 
GINA-defined poorly-controlled asthma decreased from 21 
to 15% of weeks when the dose of budesonide was increased 
fourfold from 200 to 800 µg/day. However, the FACET study11 
did not analyze whether patients with a history of frequent 
exacerbations would benefit more from the higher dose, and 
the number of exacerbations experienced by subjects in the 
year prior to study entry was not reported. Our data suggest 
that a further improvement in asthma control may be obtained 
with higher doses of Cic in case patients who have a history 
of more than one exacerbation per year, and this may be the 
subject for further study.
Responsiveness to ICS is generally much lower in 
smokers than nonsmokers with asthma.12 Data published by 
Tomlinson et al13 demonstrate that, compared with nonsmok-
ers, smokers with mild persistent asthma are insensitive to 
the therapeutic effect of low-dose ICS. The disparity of the 
response between smokers and nonsmokers appeared to 
diminish with high doses of ICS. Only 12.8% of the total 
patient population (N=367) in the current study were current 
or ex-smokers, which made it difficult to detect any change 
in effect with increasing doses.
There are some limitations to the current study. One of 
the entry criteria was that the patients in spite of a medium-
to-high dose ICS should have a poor ACQ score. It cannot 
be excluded that the lack of control shown by these patients 
may have reflected poor adherence rather than lack of effi-
cacy of the ICS; therefore, increasing the ICS dose would be 
unlikely to improve their symptoms if the adherence was not 
improved by receiving a new treatment. However, the ACQ 
score increased and the asthma control decreased over the 
3-week run-in period when all patients received Cic 160 µg/
day. This finding does not support that poor adherence prior 
to the study was a reason for our findings.
The safety findings are in agreement with the findings of 
previous studies with Cic. Cic was well tolerated, and the side 
effects did not change with increasing dose. Cortisol levels, 
or other measures of hypothalamic–pituitary–adrenal (HPA) 
axis suppression, were not measured in this study; however, 
previous studies have shown that Cic doses do not signifi-
cantly influence the HPA axis.14–16 Regarding pharyngitis, 
which is a known side effect of inhaled steroids,17 there was 
no difference in its frequency or severity between the three 
treatment arms.
Conclusion
This study confirms that once-daily Cic is overall an effective 
and well tolerated treatment for persistent moderate-to-severe 
asthma. The recommended dose of Cic 160 µg/day improves 
asthma control, and no clear additional benefits are observed 
with higher doses of up to 640 µg/day. Patients who experi-
ence more than one exacerbation per year may benefit from 
higher doses; further studies are necessary to confirm this.
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Supplementary materials
Statistical methods
•	 All the data were summarized using descriptive statistics. 
Statistical tests were two sided and conducted at the 5% 
significance level unless otherwise specified. Intention-
to-treat (ITT) and per-protocol analyses were performed 
for the primary end point based on the full and valid case 
analysis sets, respectively. All other efficacy analyses were 
performed using an ITT analysis only.
•	 The primary end point change from baseline to last visit 
in Asthma Control Questionnaire (ACQ) was analyzed 
using an analysis of covariance (ANCOVA) model includ-
ing baseline ACQ and age as covariates, and treatment 
center, sex and pre-study inhaled corticosteroid (ICS) 
dose as factors.
•	 To adjust for critical factors, a nonparametric ANCOVA 
was performed using the same factors and covariates as 
the ANCOVA model for the primary end point. Similar 
descriptive and graphical analyses were performed for 
the ACQ cutoff points 0.5, 0.75, 1.0, 1.25 and 1.5.
•	 The number of weeks with well-controlled asthma was 
defined as the number of weeks that the patient had an 
ACQ score of 0.75 or lower over the course of the study. 
Treatment comparisons were carried out using an exact 
Wilcoxon–Mann–Whitney test for the percentage of 
weeks with well-controlled asthma.
•	 The prevalence of patients with well-controlled asthma at 
the end of the study and the prevalence of patients with an 
ACQ improvement by at least 0.5 at the end of the study 
were analyzed using Fisher’s exact test.
•	 To account for differences in the time to the first of these 
events, a log-rank test was used for the analysis of the 
time to the first measurement of well-controlled asthma 
and the time to the first ACQ improvement.
•	 A Cox proportional hazards regression was computed 
using the same factors and covariates as the ANCOVA 
model for the primary end point.
•	 Asthma exacerbation rates were analyzed using a Poisson 
regression model with the same factors and covariates as 
the ANCOVA model for the primary variable.
•	 Confirmatory statistical testing was performed using a 
hierarchical approach to address multiplicity. All statisti-
cal analyses were performed using SAS Version 9.1.3 or 
later (SAS Institute Inc., Cary, NA, USA).
•	 It was calculated that a sample size of 120 in each group 
would provide almost 90% power to detect a difference in 
mean values of 0.5, assuming that the common standard 
deviation is 1.2 using a two-group t-test with a 0.05 two-
sided significance level.
Demographics
Additional demographic and baseline characteristics are 
summarized Table S1.
Concomitant medication
Exclusion criteria
Patients treated with an ICS at a stable dose between 200 and 
1000 µg fluticasone propionate/day or equivalent for a mini-
mum of 12 weeks could enter the study. The use of systemic 
glucocorticosteroids was not allowed for the entire duration 
of the study. If the administration of systemic glucocorticoste-
roids became necessary, the patient was withdrawn. Patients 
treated with one of the following nonsteroidal controllers 
(used either concurrently or in fixed combination with the 
ICS) in the 2 weeks prior to the first visit during the baseline 
period were not allowed to enter the study:
•	 Chromones (eg, inhaled disodium cromoglycate and 
inhaled nedocromil)
•	 Xanthines (eg, sustained-release theophylline and 
aminophylline)
•	 Leukotriene antagonists (eg, montelukast and zafirlukast)
•	 Lipoxygenase inhibitors (eg, zileuton)
•	 Inhaled long-acting beta-agonists (LABAs; eg, formoterol 
and salmeterol)
•	 Oral beta 2-agonists (eg, oral preparations of bambuterol, 
terbutaline, albuterol and salbutamol).
Subgroup analyses
Subgroup analyses to assess the impact of key demo-
graphic variables on the primary end point were performed 
(Table S3); data are presented for subgroups by ACQ score 
at baseline, pre-study ICS dose, body mass index, smoking 
status, completers/withdrawals and baseline forced expiratory 
volume in 1 second (FEV
1
).
Adverse events
Adverse events occurring in at least 5% of patients in any 
treatment group are shown in Table S4.
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Table S1 Additional baseline demographics in the ITT population
Variable Cic dose
Total  
(N=367)
160 μg/
day 
(N=120)
320 μg/ 
day 
(N=122)
640 μg/
day 
(N=125)
Race, n (%)
 Asian 0 0 0 0
 Black 6 (5.0) 5 (4.1) 4 (3.2) 15 (4.1)
 White 113 (94.2) 115 (94.3) 114 (91.2) 342 (93.2)
 Other 1 (0.8) 2 (1.6) 7 (5.6) 10 (2.7)
BMI group, n (%)
 ≤30 kg/m2 84 (70.0) 82 (67.2) 92 (73.6) 258 (70.3)
 >30 kg/m2 36 (30.0) 40 (32.8) 33 (26.4) 109 (29.7)
Pre-bronchodilator 
FEV1, L (SD)
2.20 (0.79) 2.35 (0.80) 2.23 (0.80) 2.26 (0.80)
Post-bronchodilator 
FEV1, L (SD)
2.71 (0.92) 2.84 (0.88) 2.76 (0.91) 2.77 (0.90)
Abbreviations: BMI, body mass index; Cic, ciclesonide; FEV1, forced expiratory 
volume in 1 second; ITT, intention-to-treat; SD, standard deviation.
Table S2 Concomitant use of short-acting beta 2-agonists in the 
ITT population
Randomized group Short-acting beta 2-agonists use
Baseline period,  
n (%)
Double-blind  
period, n (%)
160 μg/day (N=119) 110 (92.4) 108 (90.8)
320 μg/day (N=122) 105 (86.1) 103 (84.4)
640 μg/day (N=126) 108 (85.7) 108 (85.7)
Abbreviation: ITT, intention-to-treat.
Table S3 Subgroup analyses of change from baseline to last visit in ACQ score of between-treatment differences with Cic 640 μg/day 
and Cic 160 μg/day (ITT)
Variable Cic 160 μg/day 
(N=120); n
Cic 640 μg/day 
(N=125); n 
Change in ACQ score; Cic 640 μg/day  
vs Cic 160 μg/day
LS mean (SE) 95% CI Two-sided 
P-value
ACQ score at baseline
 ≤Median 59 61 -0.140 (0.1670) -0.469, 0.188 0.4019
 >Median 61 61 -0.097 (0.1670) -0.426, 0.231 0.5597
Pre-study ICS dose, μg/day FP equivalent
 Low ≤250 43 42 -0.291 (0.1985) -0.681, 0.100 0.1437
 Medium >250–≤500 72 69 -0.083 (0.1536) -0.385, 0.219 0.5887
 High >500 5 11 0.567 (0.4923) -0.402, 1.535 0.2506
BMI, kg/m2
 ≤30 84 89 -0.045 (0.1383) -0.318, 0.227 0.7429
 >30 36 33 -0.275 (0.2209) -0.710, 0.159 0.2135
Smoking status
 Never 109 106 -0.109 (0.1253) -0.355, 0.138 0.3868
 Current/former 11 16 -0.268 (0.3575) -0.971, 0.435 0.4546
Completion status
 Completer 89 97 -0.180 (0.1222) -0.420, 0.061 0.1427
 Withdrawals 31 25 0.253 (0.2245) -0.188, 0.695 0.2602
Baseline FEV1*
 ≤Median 66 52 -0.123 (0.1730) -0.464, 0.217 0.4769
 >Median 53 62 -0.076 (0.1713) -0.413, 0.261 0.6565
Notes: *Post hoc analysis. LS mean values are from ANCOVA.
Abbreviations: ACQ, Asthma Control Questionnaire; ANCOVA, analysis of covariance; BMI, body mass index; CI, confidence interval; Cic, ciclesonide; FEV1, forced 
expiratory volume in 1 second; FP, fluticasone propionate; ICS, inhaled corticosteroid; ITT, intention-to-treat; LS, least squares; SE, standard error.
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Table S4 AEs occurring in at least 5% of patients in any treatment group
System organ class;  
preferred term (MedDRA)
Cic dose during baseline 
period (3 weeks); n (%)
Cic dose during randomized,  
double-blind period (52 weeks); n (%)
Total (all), 
n (%)
160 μg/day  
(N=520)
160 μg/day 
(N=119)
320 μg/day 
(N=122)
640 μg/day 
(N=126)
Total 
(N=367)
Total  
(N=520)
All AEs 109 (21.0) 85 (71.4) 86 (70.5) 89 (70.6) 260 (70.8) 301 (57.9)
Nervous system disorders
 Headache 43 (8.3) 22 (18.5) 23 (18.9) 16 (12.7) 61 (16.6) 84 (16.2)
Infections and infestations
 Nasopharyngitis 6 (1.2) 23 (19.3) 25 (20.5) 22 (17.5) 70 (19.1) 72 (13.8)
 Bronchitis 1 (0.2) 18 (15.1) 16 (13.1) 16 (12.7) 50 (13.6) 51 (9.8)
 Influenza 0 6 (5.0) 6 (4.9) 11 (8.7) 23 (6.3) 23 (4.4)
 Sinusitis 1 (0.2) 7 (5.9) 5 (4.1) 8 (6.3) 20 (5.4) 21 (4.0)
 Rhinitis 6 (1.2) 2 (1.7) 8 (6.6) 4 (3.2) 14 (3.8) 18 (3.5)
 Pharyngitis 1 (0.2) 4 (3.4) 8 (6.6) 4 (3.2) 16 (4.4) 17 (3.3)
 Upper respiratory tract infection 3 (0.6) 7 (5.9) 1 (0.8) 6 (4.8) 14 (3.8) 15 (2.9)
Respiratory, thoracic and mediastinal disorders
 Rhinitis allergic 3 (0.6) 8 (6.7) 3 (2.5) 6 (4.8) 17 (4.6) 20 (3.8)
 Asthma 4 (0.8) 4 (3.4) 8 (6.6) 4 (3.2) 16 (4.4) 19 (3.7)
 Cough 2 (0.4) 6 (5.0) 7 (5.7) 3 (2.4) 16 (4.4) 18 (3.5)
Musculoskeletal and connective tissue disorders
 Back pain 3 (0.6) 4 (3.4) 2 (1.6) 8 (6.3) 14 (3.8) 17 (3.3)
Notes: MedDRA version 16.1. Data are n (%) in the safety analysis set. A notably lower number of AEs were reported in the baseline period (21%) compared with the 
randomized period (~71%) due to a baseline period of 3 weeks (randomized period was 52 weeks). Patients may have had more than one AE. n, number of patients with an 
event; %, percentage of patients with at least one event based on N.
Abbreviations: AE, adverse event; Cic, ciclesonide.
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